Aprea Therapeutics, Inc.
APRE
$0.90
-$0.03-3.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 83.33% | -98.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 83.33% | -98.48% | |||
| Cost of Revenue | -38.45% | -14.29% | |||
| Gross Profit | 38.58% | 8.75% | |||
| SG&A Expenses | 10.63% | -7.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.16% | -11.03% | |||
| Operating Income | 15.21% | 7.98% | |||
| Income Before Tax | 17.39% | 8.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.39% | 8.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.39% | 8.23% | |||
| EBIT | 15.21% | 7.98% | |||
| EBITDA | 15.24% | 7.99% | |||
| EPS Basic | 31.52% | 12.40% | |||
| Normalized Basic EPS | 31.53% | 12.41% | |||
| EPS Diluted | 31.52% | 12.40% | |||
| Normalized Diluted EPS | 31.53% | 12.41% | |||
| Average Basic Shares Outstanding | 20.64% | 4.76% | |||
| Average Diluted Shares Outstanding | 20.64% | 4.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||